Icariin and icaritin both enhance the anti-cancer response by modulating the function of CD4+ and CD8+ T cells, macrophages, and MDSCs in melanoma, breast, prostate, pancreatic and liver cancers [698, 704, 705]. This evidence concerns the gene CD4 and cancer.